JP2016014070A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016014070A5 JP2016014070A5 JP2015207655A JP2015207655A JP2016014070A5 JP 2016014070 A5 JP2016014070 A5 JP 2016014070A5 JP 2015207655 A JP2015207655 A JP 2015207655A JP 2015207655 A JP2015207655 A JP 2015207655A JP 2016014070 A5 JP2016014070 A5 JP 2016014070A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- oligonucleotide decoy
- pain
- cell
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 10
- 108091034117 Oligonucleotide Proteins 0.000 claims 7
- 208000002193 Pain Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 210000002569 neuron Anatomy 0.000 claims 2
- 230000008055 nociceptive signaling Effects 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 102100026865 Cyclin-dependent kinase 5 activator 1 Human genes 0.000 claims 1
- 102100027346 GTP cyclohydrolase 1 Human genes 0.000 claims 1
- 102000017679 HTR3A Human genes 0.000 claims 1
- 101000761343 Homo sapiens 5-hydroxytryptamine receptor 3A Proteins 0.000 claims 1
- 101000862581 Homo sapiens GTP cyclohydrolase 1 Proteins 0.000 claims 1
- 101001032845 Homo sapiens Metabotropic glutamate receptor 5 Proteins 0.000 claims 1
- 101001123678 Homo sapiens Phenylethanolamine N-methyltransferase Proteins 0.000 claims 1
- 101000654386 Homo sapiens Sodium channel protein type 9 subunit alpha Proteins 0.000 claims 1
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 claims 1
- 108010008858 Nitric Oxide Synthase Type I Proteins 0.000 claims 1
- 102000006538 Nitric Oxide Synthase Type I Human genes 0.000 claims 1
- 102100024611 Phosphatidylethanolamine N-methyltransferase Human genes 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 102100031367 Sodium channel protein type 9 subunit alpha Human genes 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000014509 gene expression Effects 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 108010064131 neuronal Cdk5 activator (p25-p35) Proteins 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91758307P | 2007-05-11 | 2007-05-11 | |
| US60/917,583 | 2007-05-11 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014149516A Division JP5890869B2 (ja) | 2007-05-11 | 2014-07-23 | 遺伝子発現と疼痛 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016064037A Division JP6306075B2 (ja) | 2007-05-11 | 2016-03-28 | 遺伝子発現と疼痛 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016014070A JP2016014070A (ja) | 2016-01-28 |
| JP2016014070A5 true JP2016014070A5 (https=) | 2016-05-19 |
| JP6082796B2 JP6082796B2 (ja) | 2017-02-15 |
Family
ID=40002879
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010507728A Expired - Fee Related JP5646320B2 (ja) | 2007-05-11 | 2008-05-12 | 遺伝子発現と疼痛 |
| JP2014149516A Expired - Fee Related JP5890869B2 (ja) | 2007-05-11 | 2014-07-23 | 遺伝子発現と疼痛 |
| JP2015207655A Expired - Fee Related JP6082796B2 (ja) | 2007-05-11 | 2015-10-22 | 遺伝子発現と疼痛 |
| JP2016064037A Expired - Fee Related JP6306075B2 (ja) | 2007-05-11 | 2016-03-28 | 遺伝子発現と疼痛 |
| JP2017106521A Pending JP2017148074A (ja) | 2007-05-11 | 2017-05-30 | 遺伝子発現と疼痛 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010507728A Expired - Fee Related JP5646320B2 (ja) | 2007-05-11 | 2008-05-12 | 遺伝子発現と疼痛 |
| JP2014149516A Expired - Fee Related JP5890869B2 (ja) | 2007-05-11 | 2014-07-23 | 遺伝子発現と疼痛 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016064037A Expired - Fee Related JP6306075B2 (ja) | 2007-05-11 | 2016-03-28 | 遺伝子発現と疼痛 |
| JP2017106521A Pending JP2017148074A (ja) | 2007-05-11 | 2017-05-30 | 遺伝子発現と疼痛 |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US7943591B2 (https=) |
| EP (3) | EP3199635B1 (https=) |
| JP (5) | JP5646320B2 (https=) |
| AU (1) | AU2008251320B2 (https=) |
| CA (1) | CA2723672C (https=) |
| DK (1) | DK2158316T3 (https=) |
| ES (2) | ES2619314T3 (https=) |
| HR (1) | HRP20150759T1 (https=) |
| HU (1) | HUE025701T2 (https=) |
| PL (1) | PL2158316T3 (https=) |
| PT (1) | PT2158316E (https=) |
| SI (1) | SI2158316T1 (https=) |
| WO (1) | WO2008141308A2 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2723672C (en) | 2007-05-11 | 2019-09-03 | Adynxx, Inc. | Gene expression and pain |
| RU2572826C2 (ru) | 2008-12-02 | 2016-01-20 | Чиралджен, Лтд. | Способ синтеза модифицированных по атому фосфора нуклеиновых кислот |
| CA2767253A1 (en) | 2009-07-06 | 2011-01-13 | Ontorii, Inc. | Novel nucleic acid prodrugs and methods of use thereof |
| US8609617B2 (en) | 2009-09-04 | 2013-12-17 | University Of Miami | KLF family members regulate intrinsic axon regeneration ability |
| JP5868324B2 (ja) | 2010-09-24 | 2016-02-24 | 株式会社Wave Life Sciences Japan | 不斉補助基 |
| AU2012284265B2 (en) | 2011-07-19 | 2017-08-17 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
| US20130071444A1 (en) | 2011-09-16 | 2013-03-21 | The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Healthcare System | Amphiphilic Cationic Polymers and Methods of Use Thereof |
| US9139829B2 (en) * | 2012-02-28 | 2015-09-22 | Medical Diagnostic Laboratories, Llc | SiRNA targeting ETS1 and ELK1 and method of using same in the inhibition of CIP2A gene in cancer treatment |
| EP3511022A1 (en) * | 2012-05-10 | 2019-07-17 | Adynxx, Inc. | Formulations for the delivery of active ingredients |
| CN104684923B (zh) | 2012-07-13 | 2018-09-28 | 株式会社新日本科学 | 手性核酸佐剂 |
| SG11201500239VA (en) | 2012-07-13 | 2015-03-30 | Wave Life Sciences Japan | Asymmetric auxiliary group |
| JP6453212B2 (ja) | 2012-07-13 | 2019-01-16 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | キラル制御 |
| GB201310853D0 (en) * | 2013-06-18 | 2013-07-31 | Ucb Pharma Sa | Method |
| JPWO2015108046A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤 |
| WO2015108048A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| WO2015108047A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
| ES2917473T3 (es) | 2014-01-16 | 2022-07-08 | Wave Life Sciences Ltd | Diseño quiral |
| JP6705807B2 (ja) * | 2014-08-15 | 2020-06-03 | エーダイニクス インコーポレイテッド | 疼痛を治療するためのオリゴヌクレオチドデコイ |
| JP6993230B2 (ja) * | 2015-09-09 | 2022-01-13 | アンジェス株式会社 | キメラデコイ |
| US20200017853A1 (en) * | 2016-02-29 | 2020-01-16 | Adynxx, Inc. | Compositions and methods for pain amelioration via modification of gene expression |
| US20260078376A1 (en) * | 2022-08-26 | 2026-03-19 | Core Biotherapeutics, Inc. | Oligonucleotides for the treatment of breast cancer |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6410516B1 (en) | 1986-01-09 | 2002-06-25 | President & Fellows Of Harvard College | Nuclear factors associated with transcriptional regulation |
| US5206152A (en) | 1988-04-08 | 1993-04-27 | Arch Development Corporation | Cloning and expression of early growth regulatory protein genes |
| DE3815221C2 (de) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
| US5272056A (en) | 1991-01-03 | 1993-12-21 | The Research Foundation Of State University Of New York | Modification of DNA and oligonucleotides using metal complexes of polyaza ligands |
| US5683985A (en) | 1991-04-18 | 1997-11-04 | The Salk Institute For Biological Studies | Oligonucleotide decoys and methods relating thereto |
| FR2675803B1 (fr) | 1991-04-25 | 1996-09-06 | Genset Sa | Oligonucleotides fermes, antisens et sens et leurs applications. |
| WO1995004064A1 (en) | 1993-07-29 | 1995-02-09 | The Regents Of The University Of California | Polynucleotide decoys that ihnibit mhc-ii expression and uses thereof |
| EP1350514A3 (en) | 1993-10-29 | 2004-07-07 | The Brigham And Women's Hospital, Inc. | Therapeutic use of cis-element decoys in vivo |
| WO1996016074A1 (en) | 1994-11-17 | 1996-05-30 | Taiho Pharmaceutical Co., Ltd. | Double-stranded oligonucleotide and carcinostatic agent containing the same as active ingredient |
| AU5369396A (en) | 1995-03-23 | 1996-10-08 | Research Foundation Of The State University Of New York, The | Rest protein and dna |
| JP4173539B2 (ja) | 1995-05-11 | 2008-10-29 | ラボラトアール・セローノ・ソシエテ・アノニム | Ｉｌ−６活性阻害剤 |
| EP0824918B1 (en) | 1995-05-12 | 2007-03-28 | AnGes MG, Inc. | REMEDY AND PREVENTIVE FOR DISEASES CAUSED BY NF-kappaB |
| GB9515356D0 (en) | 1995-07-26 | 1995-09-20 | Medical Res Council | Improvements in or relating to delivery of nucleic acid |
| US6265389B1 (en) | 1995-08-31 | 2001-07-24 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of oligonucleotides |
| WO1997044064A2 (en) | 1996-05-20 | 1997-11-27 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Oligonucleotides which specifically bind retroviral nucleocapsid proteins |
| US6022863A (en) | 1996-05-21 | 2000-02-08 | Yale University | Regulation of gene expression |
| JP4215219B2 (ja) | 1997-07-04 | 2009-01-28 | アンジェスＭｇ株式会社 | 脳保護剤 |
| JP3667047B2 (ja) | 1997-09-12 | 2005-07-06 | キヤノン株式会社 | 人工核酸およびその製造方法、デオキシリボフラノース化合物、リボフラノース化合物およびこれらの製造方法 |
| WO1999018792A1 (en) | 1997-10-10 | 1999-04-22 | Johns Hopkins University | Gene delivery compositions and methods |
| US6060310A (en) | 1997-11-24 | 2000-05-09 | The United States Of America As Represented By The Department Of Health And Human Services | Transcription factor decoy and tumor growth inhibitor |
| AU1656299A (en) | 1997-12-16 | 1999-07-05 | University Of Saskatchewan | Conductive metal-containing nucleic acids |
| DE69910202T2 (de) | 1998-06-02 | 2004-06-17 | Glaxo Group Ltd., Greenford | EGR-1 zur Herstellung eines Medikamentes zur Behandlung von Wunden |
| US6818626B1 (en) | 1998-07-17 | 2004-11-16 | Mirus Corporation | Chelating systems for use in the delivery of compounds to cells |
| US6867289B1 (en) | 1998-10-26 | 2005-03-15 | Board Of Regents, The University Of Texas Systems | Thio-modified aptamer synthetic methods and compositions |
| US6008048A (en) | 1998-12-04 | 1999-12-28 | Isis Pharmaceuticals Inc. | Antisense inhibition of EGR-1 expression |
| US7160869B2 (en) | 1998-12-16 | 2007-01-09 | University Of Saskatchewan | Biologically active metal-containing nucleic acids |
| AU761136B2 (en) | 1998-12-23 | 2003-05-29 | Genentech Inc. | Transfectacons comprising calcium phosphate and a nucleic acid |
| US6395029B1 (en) | 1999-01-19 | 2002-05-28 | The Children's Hospital Of Philadelphia | Sustained delivery of polyionic bioactive agents |
| US6333408B1 (en) | 1999-03-08 | 2001-12-25 | Kureha Chemical Industry Co., Ltd. | Oligonucleotides inhibitors of PAI-1 MRNA |
| FR2790955B1 (fr) | 1999-03-19 | 2003-01-17 | Assist Publ Hopitaux De Paris | Utilisation d'oligonucleotides stabilises comme principe actif antitumoral |
| CA2300328A1 (en) | 1999-09-14 | 2001-03-14 | Cardiogene Gentherap. Systeme Ag | Modulating transcription of genes in vascular cells |
| US6927027B2 (en) | 1999-12-21 | 2005-08-09 | Ingeneus Corporation | Nucleic acid multiplex formation |
| US6969704B1 (en) | 2000-08-25 | 2005-11-29 | The Trustees Of Columbia University In The City Of New York | Methods for suppressing early growth response—1protein (Egr-1) to reduce vascular injury in a subject |
| DE10049549A1 (de) | 2000-10-06 | 2002-05-02 | Markus Hecker | Modulation der Transkription pro-inflammatorischer Genprodukte |
| WO2002030355A2 (en) | 2000-10-11 | 2002-04-18 | Laura Kragie | Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase |
| EP1344536A4 (en) | 2000-11-24 | 2005-01-19 | Chugai Pharmaceutical Co Ltd | METHOD FOR REGULATING THE EFFECT OF THE EXPRESSION PRODUCT OF A GENE TRANSFERRED IN A LIVING BODY |
| WO2002066071A2 (en) | 2001-01-03 | 2002-08-29 | Thomas Jefferson University | Treatment of tissue fibrosis by blocking the sp1 transcription factor |
| AU2002241952A1 (en) | 2001-01-22 | 2002-07-30 | Genta Incorporated | Cell-proliferative disorder treatments using cre decoy oligomers, bcl-2 antisense and hybrid oligomers |
| TWI308492B (https=) | 2001-02-20 | 2009-04-11 | Anges Mg Inc | |
| AU2002254132A1 (en) | 2001-03-06 | 2002-09-19 | Sierra Sciences, Inc. | Methods and compositions for modulating telomerase reverse transcriptase (tert) expression |
| US20030166555A1 (en) | 2001-04-02 | 2003-09-04 | Alberini Cristina M. | Methods and compositions for regulating memory consolidation |
| EP1298141A1 (en) | 2001-09-27 | 2003-04-02 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Interleukin-4 (IL-4) promoter sequences specifically interacting with IRF-1 and IRF-2 |
| DE10148828B4 (de) | 2001-10-04 | 2005-05-19 | Avontec Gmbh | Modulation der Expression STAT-1-abhängiger Gene |
| US6663880B1 (en) | 2001-11-30 | 2003-12-16 | Advanced Cardiovascular Systems, Inc. | Permeabilizing reagents to increase drug delivery and a method of local delivery |
| EP1496835A4 (en) | 2002-02-01 | 2006-10-18 | Omeros Corp | COMPOSITIONS AND METHODS FOR THE SYSTEMIC SUPPRESSION OF CARTON DECOMPOSITION |
| CN1240439C (zh) | 2002-03-28 | 2006-02-08 | 南京凯基生物科技发展有限公司 | 肿瘤基因开关药物 |
| AU2002255285B2 (en) | 2002-04-26 | 2008-03-06 | Anges Mg, Inc. | Circular dumbbell decoy oligodeoxynucleotides (CDODN) containing DNA bindings sites of transcription |
| DE10242319A1 (de) | 2002-09-12 | 2004-03-25 | Avontec Gmbh | Funkionelle Korrektur der-786C/T-Varianz des humanen eNOS-Gens |
| DE10257421A1 (de) | 2002-12-09 | 2004-07-08 | Grünenthal GmbH | Regulatorische Elemente im 5'-Bereich des VR1-Gens |
| PT1585548T (pt) | 2002-12-09 | 2018-10-17 | Abraxis Bioscience Llc | Composições e métodos de administração de agentes farmacológicos |
| EP1644532A4 (en) | 2003-06-30 | 2007-11-28 | Massachusetts Inst Technology | EGR GENES AS OBJECTIVES FOR DIAGNOSIS AND TREATMENT OF SCHIZOPHRENIA |
| US20080233644A1 (en) * | 2003-09-12 | 2008-09-25 | Helen Fillmore | Chimeric Transcription Factor Decoy Oligonucleotides |
| JP2005336081A (ja) * | 2004-05-26 | 2005-12-08 | Anges Mg Inc | Ｎｒ２ｂ−ｎｍｄａ受容体の再発現抑制剤 |
| US7482158B2 (en) | 2004-07-01 | 2009-01-27 | Mathison Brian H | Composite polynucleic acid therapeutics |
| US20060293264A1 (en) | 2004-07-22 | 2006-12-28 | Grandis Jennifer R | STAT3 decoy oligonucleotides and uses therefor |
| AU2005286640A1 (en) | 2004-09-21 | 2006-03-30 | Anesiva, Inc. | Delivery of polynucleotides |
| AU2005288522B2 (en) | 2004-09-28 | 2012-06-28 | Quark Pharmaceuticals, Inc. | Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases |
| CA2583576A1 (en) | 2004-10-22 | 2006-04-27 | Anges Mg, Inc. | Chimera (double) decoy |
| US7585848B2 (en) * | 2005-01-11 | 2009-09-08 | Rush University Medical Center | Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc |
| US8268572B2 (en) * | 2005-03-04 | 2012-09-18 | Dana-Farber Cancer Institute, Inc. | Methods to identify inhibitors of Runx1-mediated expression of nociceptive receptors and ion channels |
| US7680060B2 (en) * | 2005-03-08 | 2010-03-16 | Cisco Technology, Inc. | Transferring state information in a network |
| ATE524546T1 (de) | 2005-03-25 | 2011-09-15 | Medtronic Inc | Verwendung von anti-tnf oder anti-il1-rnai zur unterdrückung der wirkung entzündungsfördernder cytokine zur lokalen schmerzbehandlung |
| ES2845146T3 (es) | 2006-10-09 | 2021-07-26 | Neurofluidics Inc | Sistema de purificación de líquido cefalorraquídeo |
| CN101686939B (zh) | 2007-04-17 | 2013-03-27 | 巴克斯特国际公司 | 用于肺部投送的核酸微粒 |
| CA2723672C (en) * | 2007-05-11 | 2019-09-03 | Adynxx, Inc. | Gene expression and pain |
| BR112013003875B1 (pt) | 2010-08-20 | 2021-10-05 | Replicor Inc | Composições farmacêuticas compreendendo complexo de quelato de oligonucleotídeo, formulação de oligonucleotídeo, e usos |
| US20140275211A1 (en) | 2011-06-21 | 2014-09-18 | Alnylam Pharmaceuticals, Inc. | Assays and methods for determining activity of a therapeutic agent in a subject |
| MY166036A (en) | 2011-07-20 | 2018-05-21 | Hospira Inc | Methods of treating pain |
| EP3511022A1 (en) | 2012-05-10 | 2019-07-17 | Adynxx, Inc. | Formulations for the delivery of active ingredients |
| MY168778A (en) | 2012-05-18 | 2018-12-04 | Replicor Inc | Oligonucleotide chelate complex-polypeptide compositions and methods |
| JP6705807B2 (ja) | 2014-08-15 | 2020-06-03 | エーダイニクス インコーポレイテッド | 疼痛を治療するためのオリゴヌクレオチドデコイ |
| US20200017853A1 (en) | 2016-02-29 | 2020-01-16 | Adynxx, Inc. | Compositions and methods for pain amelioration via modification of gene expression |
-
2008
- 2008-05-12 CA CA2723672A patent/CA2723672C/en active Active
- 2008-05-12 PT PT87553442T patent/PT2158316E/pt unknown
- 2008-05-12 HU HUE08755344A patent/HUE025701T2/en unknown
- 2008-05-12 ES ES14179247.3T patent/ES2619314T3/es active Active
- 2008-05-12 DK DK08755344.2T patent/DK2158316T3/en active
- 2008-05-12 ES ES08755344.2T patent/ES2542511T3/es active Active
- 2008-05-12 EP EP16199871.1A patent/EP3199635B1/en not_active Not-in-force
- 2008-05-12 US US12/119,435 patent/US7943591B2/en not_active Expired - Fee Related
- 2008-05-12 PL PL08755344T patent/PL2158316T3/pl unknown
- 2008-05-12 AU AU2008251320A patent/AU2008251320B2/en not_active Ceased
- 2008-05-12 EP EP14179247.3A patent/EP2818550B1/en not_active Not-in-force
- 2008-05-12 JP JP2010507728A patent/JP5646320B2/ja not_active Expired - Fee Related
- 2008-05-12 HR HRP20150759TT patent/HRP20150759T1/hr unknown
- 2008-05-12 SI SI200831461T patent/SI2158316T1/sl unknown
- 2008-05-12 WO PCT/US2008/063471 patent/WO2008141308A2/en not_active Ceased
- 2008-05-12 EP EP08755344.2A patent/EP2158316B1/en not_active Not-in-force
-
2011
- 2011-03-15 US US13/048,793 patent/US8093225B2/en not_active Expired - Fee Related
- 2011-12-09 US US13/316,321 patent/US8741864B2/en active Active - Reinstated
-
2014
- 2014-04-22 US US14/258,927 patent/US9290762B2/en not_active Expired - Fee Related
- 2014-07-23 JP JP2014149516A patent/JP5890869B2/ja not_active Expired - Fee Related
-
2015
- 2015-10-22 JP JP2015207655A patent/JP6082796B2/ja not_active Expired - Fee Related
-
2016
- 2016-02-09 US US15/019,791 patent/US10041069B2/en active Active
- 2016-03-28 JP JP2016064037A patent/JP6306075B2/ja not_active Expired - Fee Related
-
2017
- 2017-05-30 JP JP2017106521A patent/JP2017148074A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016014070A5 (https=) | ||
| WO2016205410A3 (en) | Defined multi-conjugate oligonucleotides | |
| JP2010526541A5 (https=) | ||
| EA033457B1 (ru) | Способ лечения рака у пациентов с мутациями в генах ros1, ntrk1, ntrk2 и/или ntrk3 | |
| WO2017078499A3 (ko) | 단백질 타이로신 탈인산화효소 억제제를 포함하는 신경염증성 질환의 예방 또는 치료용 조성물 | |
| EP4218816A3 (en) | Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii | |
| JP2016528301A5 (https=) | ||
| JP2018512876A5 (https=) | ||
| EA201290837A1 (ru) | Лечение волчаночного нефрита с применением лаквинимода | |
| JP2010059183A5 (https=) | ||
| MX2021011563A (es) | Derivados de 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmaceuticas que los incluyen. | |
| EP4650364A3 (en) | Materials and methods for treatment of pain related disorders | |
| WO2017022962A8 (ko) | Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 | |
| JP2017532343A5 (https=) | ||
| JP2015514778A5 (https=) | ||
| JP2016523260A5 (https=) | ||
| RU2016150116A (ru) | Ингибитор пролиферации раковых стволовых клеток | |
| RU2015140572A (ru) | Способы лечения колоректального рака | |
| JP2016531894A5 (https=) | ||
| JP2016512817A5 (https=) | ||
| WO2017106175A3 (en) | USE OF sGC STIMULATORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DYSFUNCTION | |
| WO2015112902A3 (en) | CYSTATHIONINE-(gamma)-LYASE (CSE) INHIBITORS FOR TREATING PAIN | |
| WO2019060522A3 (en) | Thiomorpholino oligonucleotides for the treatment of muscular dystrophy | |
| EP3594346A4 (en) | ANTISENS OLIGONUCLEOTIDE AND COMPOSITION FOR THE PREVENTION OR TREATMENT OF TYPE IA GLYCOGEN STORAGE DISEASE | |
| JP2017529834A5 (https=) |